Proline-rich transmembrane protein 2 knock-in mice present dopamine-dependent motor deficits.

L-dopa Prrt2 dopamine paroxysmal kinesigenic dyskinesia rotarod

Journal

Journal of biochemistry
ISSN: 1756-2651
Titre abrégé: J Biochem
Pays: England
ID NLM: 0376600

Informations de publication

Date de publication:
04 Oct 2023
Historique:
received: 05 08 2023
revised: 19 09 2023
accepted: 26 09 2023
medline: 4 10 2023
pubmed: 4 10 2023
entrez: 4 10 2023
Statut: aheadofprint

Résumé

Mutations of proline-rich transmembrane protein 2 (PRRT2) lead to dyskinetic disorders such as paroxysmal kinesigenic dyskinesia (PKD), which is characterized by attacks of involuntary movements precipitated by suddenly initiated motion, and some convulsive disorders. Although previous studies have shown that PKD might be caused by cerebellar dysfunction, PRRT2 has not been sufficiently analyzed in some motor-related regions including the basal ganglia, where dopaminergic neurons are most abundant in the brain. Here, we generated several types of Prrt2 knock-in (KI) mice harboring mutations, such as c.672dupG, that mimics the human pathological mutation c.649dupC and investigated the contribution of Prrt2 to dopaminergic regulation. Regardless of differences in the frameshift sites, all truncating mutations abolished Prrt2 expression within the striatum and cerebral cortex, consistent with previous reports of similar Prrt2 mutant rodents, confirming the loss-of-function nature of these mutations. Importantly, administration of L-dopa, a precursor of dopamine, exacerbated rotarod performance, especially in Prrt2-KI mice. These findings suggest that dopaminergic dysfunction in the brain by the PRRT2 mutation might be implicated in a part of motor symptoms of PKD and related disorders.

Identifiants

pubmed: 37793168
pii: 7289213
doi: 10.1093/jb/mvad074
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the Japanese Biochemical Society. All rights reserved.

Auteurs

Daisuke Hatta (D)

Department of Genome-based Drug Discovery, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8521, Japan.

Kaito Kanamoto (K)

Department of Genome-based Drug Discovery, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8521, Japan.

Shiho Makiya (S)

Department of Genome-based Drug Discovery, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8521, Japan.

Kaori Watanabe (K)

Department of Genome-based Drug Discovery, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8521, Japan.

Tatsuya Kishino (T)

Division of Functional Genomics, Research Center for Advanced Genomics, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan.
Leading Medical Research Core Unit, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan.

Akira Kinoshita (A)

Department of Human Genetics, Atomic Bomb Disease Institute, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan.
Leading Medical Research Core Unit, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan.

Koh-Ichiro Yoshiura (KI)

Department of Human Genetics, Atomic Bomb Disease Institute, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan.
Leading Medical Research Core Unit, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan.

Naohiro Kurotaki (N)

Department of Human Genetics, Atomic Bomb Disease Institute, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan.

Keiro Shirotani (K)

Department of Genome-based Drug Discovery, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8521, Japan.
Leading Medical Research Core Unit, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan.

Nobuhisa Iwata (N)

Department of Genome-based Drug Discovery, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8521, Japan.
Leading Medical Research Core Unit, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan.

Classifications MeSH